Bispecific Antibodies MarketSize and Trends

Key Developments in the bispecific antibodies market

The global bispecific antibodies market is expected to witness significant growth, owing to increasing research and development of novel bispecific antibodies. For instance, in January 2019, the Chinese Academy of Medical Sciences & Peking Union Medical College developed a new bispecific aptamer that enhances immune cytotoxicity against MUC1-positive tumor cells.

Moreover, in September 2018, researchers from China Pharmaceutical University constructed and expressed a fully human, bispecific, single-chain diabody that can bind to vascular endothelial growth factor 165 (VEGF165) and programmed death-1 in Pichia pastoris.

In August 2018, UCB Pharma, a scientific research company based in Belgium, conducted research on the molecular factors in bispecific antibody multimerisation and revealed that the monomer level of single-chain variable fragment-containing bispecific antibody formats can be increased by conversion of the single-chain variable fragment to a disulfide-stabilized single-chain variable fragment.

Catumaxomab – the first Bispecific antibody boost growth of the bispecific antibodies market

As of 2015, over 60 different BsAb formats have been developed, with some making their way into the clinical trials. Bispecific antibodies market growth is increasing due to the limitation of monoclonal antibodies in drug resistance and failure to respond in treatment. Hence, the bispecific antibodies market is projected to gain significant growth traction in the near future.

Catumaxomab is a rat – mouse hybrid monoclonal bispecific trifunctional antibody used to treat malignant ascites. It was developed by Fresenius Biotech and Trion Pharma. Catumaxomab was approved in Europe in 2009 and is undergoing clinical trials in the U.S. Sold under the brand name Removab, Catumaxomab is administered to patients with EpCAM-poisitve carcinoma.

Increasing investments to harness the potential of highly effective BsAb Drug Therapy

Various pharmaceutical companies are actively involved in development and manufacture of bispecific antibodies. MedImmune, LLC and Abpro, collaborated in December 2016 to develop novel bispecific antibody, Ang2-VEGF, which targets angiopoietin-2 and vascular endothelial growth factor. Government funding is projected to further encourage research and development in this field.